The CYP1B1 antibody is a crucial tool for studying the cytochrome P450 family 1 subfamily B member 1 (CYP1B1), an enzyme involved in metabolizing endogenous compounds and xenobiotics. CYP1B1 plays roles in steroidogenesis, particularly in estrogen metabolism, and is implicated in oxidative stress responses. Its overexpression is linked to various cancers, including breast, prostate, and colorectal cancers, where it may promote tumor progression by generating carcinogenic metabolites or inducing drug resistance. Additionally, CYP1B1 mutations are associated with primary congenital glaucoma due to impaired ocular development. The antibody, typically raised against specific epitopes of the human CYP1B1 protein, enables detection and quantification in tissues or cell lysates via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use it to explore CYP1B1's tissue distribution, regulatory mechanisms, and pathological roles, particularly in carcinogenesis and chemoresistance studies. Commercially available monoclonal and polyclonal variants vary in specificity, requiring validation for cross-reactivity with other CYP isoforms. Recent studies also investigate CYP1B1 as a potential therapeutic target, with antibodies aiding in validating siRNA knockdown or inhibitor efficacy. Its utility extends to biomarker research for early cancer detection and personalized treatment strategies.